A call to action: MTHFR polymorphisms should not be a part of inherited thrombophilia testing
- PMID: 35702587
- PMCID: PMC9175241
- DOI: 10.1002/rth2.12739
A call to action: MTHFR polymorphisms should not be a part of inherited thrombophilia testing
Abstract
Testing for polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene is still a standard part of thrombophilia testing in many laboratories. However, it is clear that these polymorphisms are not risk factors for arterial or venous thrombosis and therefore should not be part of thrombophilia testing. Eliminating MTHFR from thrombophilia testing will reduce patient concerns and health care costs.
Keywords: MTHFR; guidelines; homocysteine; testing; thrombophilia.
© 2022 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH).
References
-
- Kang SS, Wong PW, Zhou JM, et al. Thermolabile methylenetetrahydrofolate reductase in patients with coronary artery disease. Metabolism. 1988;37:611‐613. - PubMed
-
- Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111‐113. - PubMed
-
- Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab. 1998;64(3):169‐172. - PubMed
-
- Long S, Goldblatt J. MTHFR genetic testing: controversy and clinical implications. Aust Fam Physician. 2016;45(4):237‐240. - PubMed
-
- Hickey SE, Curry CJ, Toriello HV. ACMG practice guideline: lack of evidence for MTHFR polymorphism testing. Genet Med. 2013;15(2):153‐156. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous
